Clinical Trial

Reduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasopharyngeal Carcinoma

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Through multicenter, open-label, randomised clinical trials, we intend to demonstrate that radiotherapy with reduced dose could significantly reduce the incidence of radiotherapy toxicities, improve the quality of life of patients while ensuring the tumor control rates for NPC patients staged as II-III who are sensitive to induction chemotherapy (imaging evaluation of CR/PR and EBV DNA copy number decreased to 0 copies/mL after induction chemotherapy)
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2020-06-24.
Trial Details
NCT Number NCT04448522
Lead Sponsor Sun Yat-sen University
Collaborators: National Cancer Centre, Singapore, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Zhongshan People's Hospital, Guangdong, China, Yuebei People's Hospital, Wuzhou Red Cross Hospital
Conditions Nasopharyngeal Carcinoma, Radiotherapy, Chemotherapy
Enrollment 508 participants
Start Date 2020-08-18
Primary Completion 2026-08 (estimated)
Study Completion 2028-08 (estimated)
Updated on ClinicalTrials.gov 2020-09-28